| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | NaN | 935 | 613 | 553 |
| Restricted cash and restricted cash equivalents | NaN | 3,161 | 1,024 | NaN |
| Cash | 1,020 | NaN | NaN | NaN |
| Restricted cash | 3,085 | NaN | NaN | NaN |
| Prepaid expenses | 1,845 | 2,209 | 2,013 | 1,857 |
| Restricted cash equivalents, current | NaN | NaN | NaN | 745 |
| Other current assets | 205 | 141 | 127 | 116 |
| Total current assets | 6,155 | 6,446 | 3,777 | 3,271 |
| Property, plant and equipment, gross-Computer Equipment | NaN | 5 | NaN | NaN |
| Accumulated depreciation-Computer Equipment | NaN | 5 | NaN | NaN |
| Property, plant and equipment, gross-Software And Software Development Costs | NaN | 218 | NaN | NaN |
| Accumulated depreciation-Software And Software Development Costs | NaN | 218 | NaN | NaN |
| Property, plant and equipment, gross-Furniture And Fixtures | NaN | 118 | NaN | NaN |
| Accumulated depreciation-Furniture And Fixtures | NaN | 118 | NaN | NaN |
| Property, plant and equipment, gross-Leasehold Improvements | NaN | 171 | NaN | NaN |
| Accumulated depreciation-Leasehold Improvements | NaN | 167 | NaN | NaN |
| Property and equipment, net | 2 | 4 | 8 | 19 |
| Right-of-use assets, operating leases | 71 | 175 | 277 | 377 |
| Other long-term assets | 4,495 | 3,387 | 2,279 | 1,924 |
| Total non-current assets | 4,568 | 3,566 | 2,564 | 2,320 |
| Total assets | 10,723 | 10,012 | 6,341 | 5,591 |
| Accounts payable | 3,810 | 2,911 | 1,456 | 2,879 |
| Accrued liabilities | 7,349 | 6,202 | 4,804 | 5,414 |
| Current portion of lease liability, operating leases | 80 | 193 | 305 | 413 |
| Interest on related party loan payable | NaN | NaN | 514 | 294 |
| Total current liabilities | 11,239 | 9,306 | 7,079 | 9,000 |
| Lease liability, operating leases | NaN | 0 | 0 | 0 |
| Loan payable to related party | 32,870 | 27,018 | 18,712 | 10,962 |
| Interest on related party loan payable | 1,286 | 855 | NaN | NaN |
| Total non-current liabilities | 34,156 | 27,873 | 18,712 | 10,962 |
| Total liabilities | 45,395 | 37,179 | 25,791 | 19,962 |
| Common shares, no par value, unlimited authorized shares, 2,552,429 issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 459,771 | 459,771 | 459,771 | 459,771 |
| Additional paid-in capital | 83,942 | 83,813 | 83,771 | 83,727 |
| Accumulated other comprehensive loss | -4,316 | -4,316 | -4,316 | -4,316 |
| Accumulated deficit | -574,069 | -566,435 | -558,676 | -553,553 |
| Total shareholders' deficit | -34,672 | -27,167 | -19,450 | -14,371 |
| Total liabilities and shareholders' deficit | 10,723 | 10,012 | 6,341 | 5,591 |
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)